Business context and reporting period
The supplied filing is IMARA Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 15, 2022. It is not filed under the requested company name, Enliven Therapeutics, Inc.; investors should verify the issuer and ticker (IMRA) before relying on this summary. The filing reports annual results, not a standalone fourth quarter.
IMARA was a clinical-stage biopharmaceutical company with no approved products or product revenue. Its lead candidate, tovinontrine (IMR-687), was in Phase 2b trials for sickle cell disease (SCD) and β-thalassemia; the company planned a Phase 2 heart-failure-with-preserved-ejection-fraction (HFpEF) trial in 2022. IMR-261 was in research and preclinical development.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $38.4 million | $32.2 million |
| General and administrative expense | $13.0 million | $9.5 million |
| Total operating expenses / operating loss | $51.4 million | $41.7 million |
| Net loss | $51.4 million | $41.4 million |
| Net loss per share | $2.37 | $3.53 |
| Net cash used in operating activities | $46.8 million | $37.4 million |
Operating expenses rose about 23%, primarily from higher clinical-development and manufacturing costs, increased headcount and public-company costs. Loss per share improved largely alongside a higher weighted-average share count and the absence of 2020’s preferred-stock accretion; the underlying net loss increased. Profitability and operating margins are not meaningful for this pre-revenue company.
At December 31, 2021, cash and cash equivalents were $48.3 million and short-term investments were $42.0 million, totaling $90.3 million. Current assets were $92.7 million, current liabilities $7.2 million, and total liabilities $7.6 million. No borrowings or material financial debt are disclosed; liabilities primarily include payables, accruals and operating leases. Stockholders’ equity was $86.0 million and accumulated deficit was $147.5 million.
Financing cash flow was $49.1 million, including $46.8 million net proceeds from the July 2021 stock offering and $1.4 million net proceeds from at-the-market sales. Shares outstanding increased from 17.5 million to 26.3 million during 2021. The company had no committed external funding source.
Material changes and operating developments
- Net loss widened from $41.4 million to $51.4 million; operating cash use increased by $9.4 million.
- R&D spending increased by $6.3 million, and G&A by $3.5 million.
- The Ardent Phase 2b SCD trial completed enrollment. In November 2021, following written FDA advice, the primary endpoint changed from fetal hemoglobin response to annualized vaso-occlusive crisis rate; HbF remained a key secondary endpoint.
- A pre-specified interim analysis in Forte, the β-thalassemia trial, found a tolerability profile described as acceptable and a trend toward reduced transfusion burden in the high-dose group. The reported response counts were small, and placebo response was substantial.
Outlook, risks and unusual items
Management expected year-end cash and investments to fund operations substantially through the first quarter of 2023, based on assumptions that could prove incorrect. The filing and auditor’s report nevertheless state that substantial doubt exists about the company’s ability to continue as a going concern within one year after filing; the financial statements contain no adjustments for the outcome of that uncertainty. Management expected to need additional capital in the near term. Further equity financing could dilute shareholders, while unavailable financing could force delays, reductions or termination of development programs.
Management expected Ardent and Forte interim data in the first week of April 2022 and final data in the second half of 2022, and planned to start the HFpEF trial in the second quarter of 2022. These are forward-looking plans, not reported outcomes. The HFpEF trial’s planned primary endpoint was change in NT-proBNP; the filing cautions that regulators may not consider this biomarker sufficient to establish clinical benefit.
Key risks include dependence on tovinontrine, uncertain clinical efficacy and safety, clinical-trial execution and enrollment, COVID-19-related disruptions, reliance on third-party manufacturers and service providers, competition, intellectual-property and licensing risks, and the need for additional financing. The company reported no material legal proceedings. The independent auditor issued an unqualified opinion on the financial statements while highlighting the going-concern uncertainty. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal-control effectiveness because the company was exempt.
Investor facts to verify
- Confirm the filing’s issuer identity: IMARA Inc. (IMRA), not Enliven Therapeutics, Inc.
- Check subsequent financing, cash runway and any later going-concern developments against the stated first-quarter 2023 runway and substantial-doubt warning.
- Review final Ardent and Forte results, including the implications of the changed Ardent primary endpoint and the small interim Forte response groups.
- Verify whether the planned HFpEF trial began and whether NT-proBNP was accepted or supplemented by clinically meaningful endpoints.
- Assess dilution from the 2021 offerings, remaining shelf and at-the-market capacity, and equity-plan share reserves.